Abstract:We read with great interest the recent article by Dr. Cohen and colleagues (1). The authors are to be commended for their contribution toward a greater understanding of headache disorders in service members. In their recent study the authors evaluated a cohort of evacuees from Operations Iraqi and Enduring Freedom for primary headache diagnoses and several factors related to return to duty. Although it was not surprising that the most common primary headache diagnosis in this population was post-concussion headache (34.1%), it is notable that the authors found a migraine prevalence of 30% in their cohort of predominantly male service members (88%). We believe that the high prevalence of migraine in predominantly male service members who are being considered for return to active duty may warrant special consideration. In a recent general population study of over 5,600 participants, the odds of post-traumatic stress disorder (PTSD) were threeto four-fold greater in men with migraine as compared to women with migraine (2). Available evidence also suggests that life-threatening traumas, such as occur with military combat, are associated with an 8.5-fold increase in PTSD risk compared with other types of trauma (3). Furthermore, almost 25% of migraineurs with PTSD report combat as the most significant traumatic life event associated with their PTSD (4). Thus, the high prevalence of migraine in service members being considered for return to combat, as well as the strong association between migraine and PTSD, underscore the importance of giving serious consideration to enhanced clinical vigilance and aggressive treatment of both disorders in service members (1,2,4). This raises another point that deserves greater attention from Cohen and colleagues’ recent study. Interestingly, the authors found that the use of betablockers was the factor most strongly associated with failure to return to duty (odds ratio (OR) 0.26; 95% confidence interval (CI) 0.12–0.61; p1⁄4 0.002), moreso than opioid use (OR 0.41; 95% CI 0.26–0.63; p< 0.001) and even traumatic brain injury (OR 0.50, 95% CI 0.29–0.82; p1⁄4 0.01). The authors hypothesized that this may be due to greater disease burden (1). We agree that beta-blocker use may be a risk marker for migraine severity and greater disease burden. In addition, we hypothesize that the coexistence of other migraine comorbidities, such as hypertension and even PTSD, for which beta-blockers may also be utilized, could play a role, (albeit controversial). It is also worthy of note that previous research has found lower heart rate variability in patients with combat-related PTSD (5). Thus, one should consider the possibility that the medical indications for prescribing beta-blockers, or perhaps the medications themselves, could potentially predispose patients to greater vulnerability to PTSD, and consequently contribute to lower rates of return to duty. Regardless of the mechanisms, the authors’ current findings suggest that clinicians treating service members with migraine should, at the very least, consider use of migraine preventives other than beta-blockers (e.g. tricyclic antidepressants, or anti-epileptics such as topirimate and gabapentin), and should perhaps be cautioned against beta-blocker use for migraine prevention pending further clarification. Further research in regard to the special considerations of headache treatment in service members in general (and in male service members in particular), as well as research to quantify the independent and joint effects of migraine, and migraine treatments (particularly with beta-blockers), on health outcomes in service members, is warranted.

[How many testicular lobules does a human testicle contain? Reexamination of an old problem].

Enhancement of gum Arabic/casein microencapsulation on the survival of Lactiplantibacillus plantarum in the stimulated gastrointestinal conditions

Microencapsulation of Bacillus Smithii XY1 by Spray Drying and Evaluation for Treatment of Inflammatory Bowel Disease

Carboxymethyl Konjac Glucomannan-Chitosan Complex Nanogels Stabilized Emulsions Incorporated into Alginate As Microcapsule Matrix for Intestinal-Targeted Delivery of Probiotics: in Vivo and in Vitro Studies.

Enhancing storage and gastroprotective viability of Lactiplantibacillus plantarum encapsulated by sodium caseinate-inulin-soy protein isolates composites carried within carboxymethyl cellulose hydrogel

Enhancement of existing Web applications to support audio and musical tools

Encapsulation of Lactiplantibacillus plantarum with casein-gellan gum emulsions to enhance its storage, pasteurization, and gastrointestinal survival

Microencapsulation of Lactobacillus plantarum with Improved Survivability Using Pufferfish Skin Gelatin-Based Wall Materials

Properties and stability of Lactiplantibacillus plantarum AB6-25 and Saccharomyces boulardii T8-3C single and double-layered microcapsules containing Na-alginate and/or demineralized whey powder with lactobionic acid

Protective Effects of Laminaria japonica Polysaccharide Composite Microcapsules on the Survival of Lactobacillus plantarum during Simulated Gastrointestinal Digestion and Heat Treatment

Preparation of Ca-alginate-whey protein isolate microcapsules for protection and delivery of L. bulgaricus and L. paracasei

In Vitro and In Vivo Characterisation of Lactiplantibacillus plantarum LAB12 in Pea Protein-Alginate Microcapsules

Microencapsulation and Application of Probiotic Bacteria Lactiplantibacillus plantarum 299v Strain

Outcomes of children of extremely low birthweight and gestational age in the 1990s.

Microencapsulation of Lactobacillus salivarious Li01 for enhanced storage viability and targeted delivery to gut microbiota

Lactiplantibacillus plantarum encapsulated by chitosan-alginate and soy protein isolate-reducing sugars conjugate for enhanced viability

Ambient storage of microencapsulated Lactobacillus plantarum ST-III by complex coacervation of type-A gelatin and gum arabic

Comment on: “Headaches during war: Analysis of presentation, treatment, and factors associated with outcome”

Encapsulation of Lactiplantibacillus plantarum probiotics through cross-linked chitosan and casein for improving their viability, antioxidant and detoxification

Fabrication of whey protein/pectin double layer microcapsules for improving survival of Lacticaseibacillus rhamnosus ZFM231

Solving the delivery of Lactococcus lactis: Improved survival and storage stability through the bioencapsulation with different carriers